nach oben

04.04.2024 | Global Cardiovascular Health (L Sperling and D Gaita, Section Editors)

Colchicine for the Prevention of Cardiovascular Disease: Potential Global Implementation

verfasst von: Robert S. Zhang, Brittany N Weber, Diego Araiza-Garaygordobil, Michael S. Garshick

Erschienen in: Current Cardiology Reports

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Targeting traditional cardiovascular risk factors is effective in reducing recurrent cardiovascular events, yet the presence of residual cardiovascular risk due to underlying systemic inflammation is a largely unaddressed opportunity. This review aims to comprehensively assess the evolving role of colchicine as a therapeutic approach targeting residual inflammatory risk in the context of those with coronary artery disease (CAD).

Recent Findings

Inflammation plays a significant role in promoting atherosclerosis, and targeting anti-inflammatory pathways has the potential to decrease cardiovascular events. Low-dose colchicine (0.5 mg/day orally), when added to guideline-directed medical care for CAD, safely decreases major adverse cardiovascular events (MACE) by 31% in stable atherosclerosis patients and 23% in those after recent myocardial infarctions. Meta-analyses of recent randomized control trials further support both the efficacy and safety of colchicine, particularly when added to other standard cardiovascular therapies, including statin therapy. The European Society of Cardiology and other national guidelines endorse the use of low-dose colchicine in patients across the spectrum of CAD. Recently, colchicine was FDA-approved in the United States as the first anti-inflammatory therapy for the reduction of cardiovascular events. In a period of a rising incidence of CAD across the globe, colchicine represents a unique opportunity to decrease MACE due to its large magnitude of benefits and general affordability. However, challenges with drug interactions must be addressed, especially in those regions where HIV, hepatitis, and tuberculosis are prevalent.

Summary

Colchicine is safe and effective at reducing cardiovascular events across a broad spectrum of coronary syndromes. The ability to simultaneously target traditional risk factors and mitigate residual inflammatory risk marks a substantial advancement in cardiovascular prevention strategies, heralding a new era in the global battle against CAD.

Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, et al. Global burden of cardiovascular diseases and risk factors, 1990–2019: update from the GBD 2019 Study. J Am Coll Cardiol. 2020;76(25):2982–3021. https://doi.org/10.1016/j.jacc.2020.11.010.CrossRefPubMedPubMedCentral

Zhao D. Epidemiological features of cardiovascular disease in Asia. JACC: Asia. 2021;1(1):1–13. https://doi.org/10.1016/j.jacasi.2021.04.007.CrossRefPubMedPubMedCentral

Das Pradhan A, Glynn RJ, Fruchart J-C, MacFadyen JG, Zaharris ES, Everett BM, et al. Triglyceride lowering with pemafibrate to reduce cardiovascular risk. N Engl J Med. 2022;387(21):1923–34. https://doi.org/10.1056/NEJMoa2210645.CrossRefPubMed

Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2018;380(1):11–22. https://doi.org/10.1056/NEJMoa1812792.CrossRefPubMed

Nicholls SJ, Lincoff AM, Garcia M, Bash D, Ballantyne CM, Barter PJ, et al. Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH randomized clinical trial. JAMA. 2020;324(22):2268–80. https://doi.org/10.1001/jama.2020.22258.CrossRefPubMedPubMedCentral

Ridker PM, Danielson E, Fonseca FAH, Genest J, Gotto AM, Kastelein JJP, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195–207. https://doi.org/10.1056/NEJMoa0807646.CrossRefPubMed

Ridker PM, Everett BM, Pradhan A, MacFadyen JG, Solomon DH, Zaharris E, et al. Low-dose methotrexate for the prevention of atherosclerotic events. N Engl J Med. 2018;380(8):752–62. https://doi.org/10.1056/NEJMoa1809798.CrossRefPubMedPubMedCentral

Nicholls SJ, Kastelein JJP, Schwartz GG, Bash D, Rosenson RS, Cavender MA, et al. Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial. JAMA. 2014;311(3):252–62. https://doi.org/10.1001/jama.2013.282836.CrossRefPubMed

O’Donoghue ML, Braunwald E, White HD, Steen DL, Lukas MA, Tarka E, et al. Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial. JAMA. 2014;312(10):1006–15. https://doi.org/10.1001/jama.2014.11061.CrossRefPubMed

10.

Darapladib for preventing ischemic events in stable coronary heart disease. New Eng J Med. 2014;370(18):1702–11. https://doi.org/10.1056/NEJMoa1315878.

11.

Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119–31. https://doi.org/10.1056/NEJMoa1707914.CrossRefPubMed

12.

Dasgeb B, Kornreich D, McGuinn K, Okon L, Brownell I, Sackett DL. Colchicine: an ancient drug with novel applications. Br J Dermatol. 2018;178(2):350–6. https://doi.org/10.1111/bjd.15896.CrossRefPubMedPubMedCentral

13.

Nerlekar N, Beale A, Harper RW. Colchicine–a short history of an ancient drug. Med J Aust. 2014;201(11):687–8. https://doi.org/10.5694/mja14.00846.CrossRefPubMed

14.

Adler Y, Charron P, Imazio M, Badano L, Barón-Esquivias G, Bogaert J, et al. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: the task force for the diagnosis and management of pericardial diseases of the European Society of Cardiology (ESC)endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2015;36(42):2921–64. https://doi.org/10.1093/eurheartj/ehv318.CrossRefPubMed

15.

Esatoglu SN, Hatemi G. Update on the treatment of Behçet’s syndrome. Intern Emerg Med. 2019;14(5):661–75. https://doi.org/10.1007/s11739-019-02035-1.CrossRefPubMed

16.

Ozen S, Demirkaya E, Erer B, Livneh A, Ben-Chetrit E, Giancane G, et al. EULAR recommendations for the management of familial Mediterranean fever. Ann Rheum Dis. 2016;75(4):644–51. https://doi.org/10.1136/annrheumdis-2015-208690.CrossRefPubMed

17.

Chiabrando JG, Bonaventura A, Vecchié A, Wohlford GF, Mauro AG, Jordan JH, et al. Management of acute and recurrent pericarditis. J Am Coll Cardiol. 2020;75(1):76–92. https://doi.org/10.1016/j.jacc.2019.11.021.CrossRefPubMed

18.

Libby P, Bonow R, Mann D, Tomaselli G, Bhatt D, Solomon S. Braunwald’s heart disease : a textbook of cardiovascular medicine. 12th ed. Philadelphia: Elsevier; 2021.

19.

Fernandez DM, Rahman AH, Fernandez NF, Chudnovskiy A, Amir ED, Amadori L, et al. Single-cell immune landscape of human atherosclerotic plaques. Nat Med. 2019;25(10):1576–88. https://doi.org/10.1038/s41591-019-0590-4.CrossRefPubMedPubMedCentral

20.

Leung YY, Yao Hui LL, Kraus VB. Colchicine–update on mechanisms of action and therapeutic uses. Semin Arthritis Rheum. 2015;45(3):341–50. https://doi.org/10.1016/j.semarthrit.2015.06.013.CrossRefPubMedPubMedCentral

21.

Martínez GJ, Celermajer DS, Patel S. The NLRP3 inflammasome and the emerging role of colchicine to inhibit atherosclerosis-associated inflammation. Atherosclerosis. 2018;269:262–71. https://doi.org/10.1016/j.atherosclerosis.2017.12.027.CrossRefPubMed

22.

Richette P, Frazier A, Bardin T. Pharmacokinetics considerations for gout treatments. Expert Opin Drug Metab Toxicol. 2014;10(7):949–57. https://doi.org/10.1517/17425255.2014.915027.CrossRefPubMed

23.

Slobodnick A, Shah B, Pillinger MH, Krasnokutsky S. Colchicine: old and new. Am J Med. 2015;128(5):461–70. https://doi.org/10.1016/j.amjmed.2014.12.010.CrossRefPubMed

24.

Niel E, Scherrmann J-M. Colchicine today. Joint Bone Spine. 2006;73(6):672–8. https://doi.org/10.1016/j.jbspin.2006.03.006.CrossRefPubMed

25.

Chappey ON, Niel E, Wautier JL, Hung PP, Dervichian M, Cattan D, et al. Colchicine disposition in human leukocytes after single and multiple oral administration. Clin Pharmacol Ther. 1993;54(4):360–7. https://doi.org/10.1038/clpt.1993.161.CrossRefPubMed

26.

Robinson PC, Terkeltaub R, Pillinger MH, Shah B, Karalis V, Karatza E, et al. Consensus statement regarding the efficacy and safety of long-term low-dose colchicine in gout and cardiovascular disease. Am J Med. 2022;135(1):32–8. https://doi.org/10.1016/j.amjmed.2021.07.025.CrossRefPubMed

27.

Rochdi M, Sabouraud A, Girre C, Venet R, Scherrmann JM. Pharmacokinetics and absolute bioavailability of colchicine after i.v. and oral administration in healthy human volunteers and elderly subjects. Eur J Clin Pharmacol. 1994;46(4):351–4. https://doi.org/10.1007/bf00194404.CrossRefPubMed

28.

Wiggins BS, Saseen JJ, Page RL, Reed BN, Sneed K, Kostis JB, et al. Recommendations for management of clinically significant drug-drug interactions with statins and select agents used in patients with cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2016;134(21):e468–95. https://doi.org/10.1161/CIR.0000000000000456.CrossRefPubMed

29.

•• Tardif J-C, Kouz S, Waters DD, Bertrand OF, Diaz R, Maggioni AP, et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med. 2019;381(26):2497–505. https://doi.org/10.1056/NEJMoa1912388. In this randomized control trial, among patients who experienced myocardial infarction within the past 30 days, the use of colchicine was associated with a decrease in the primary composite endpoint, encompassing death from cardiovascular causes, resuscitated cardiac arrest, recurrent MI, stroke, or urgent coronary revascularization, over a median follow-up period of 22.6 months.CrossRefPubMed

30.

•• Nidorf SM, Fiolet ATL, Mosterd A, Eikelboom JW, Schut A, Opstal TSJ, et al. Colchicine in patients with chronic coronary disease. N Engl J Med. 2020;383(19):1838–47. https://doi.org/10.1056/NEJMoa2021372. The results of this randomized control trial reveal that among individuals with chronic coronary disease, colchicine led to a significant decrease in the composite outcome encompassing cardiovascular death, spontaneous myocardial infarction, ischemic stroke, or ischemia-driven coronary revascularization throughout a median follow-up period of 28.6 months.CrossRefPubMed

31.

Samuel M, Tardif JC, Bouabdallaoui N, Khairy P, Dubé MP, Blondeau L, et al. Colchicine for secondary prevention of cardiovascular disease: a systematic review and meta-analysis of randomized controlled trials. Can J Cardiol. 2021;37(5):776–85. https://doi.org/10.1016/j.cjca.2020.10.006.CrossRefPubMed

32.

Andreis A, Imazio M, Avondo S, Casula M, Paneva E, Piroli F, et al. Adverse events of colchicine for cardiovascular diseases: a comprehensive meta-analysis of 14 188 patients from 21 randomized controlled trials. J Cardiovasc Med. 2021;22(8):637–44. https://doi.org/10.2459/jcm.0000000000001157.CrossRef

33.

Stewart S, Yang KCK, Atkins K, Dalbeth N, Robinson PC. Adverse events during oral colchicine use: a systematic review and meta-analysis of randomised controlled trials. Arthritis Res Ther. 2020;22(1):28. https://doi.org/10.1186/s13075-020-2120-7.CrossRefPubMedPubMedCentral

34.

Tong DC, Quinn S, Nasis A, Hiew C, Roberts-Thomson P, Adams H, et al. Colchicine in Patients with acute coronary syndrome. Circulation. 2020;142(20):1890–900. https://doi.org/10.1161/CIRCULATIONAHA.120.050771.CrossRefPubMed

35.

Galli M, Princi G, Crea F, D’Amario D. Colchicine and risk of non-cardiovascular death in patients with coronary artery disease: a pooled analysis underling possible safety concerns. European Heart Journal - Cardiovascular Pharmacotherapy. 2020;7(3):e18–9. https://doi.org/10.1093/ehjcvp/pvaa137.CrossRef

36.

Finkelstein Y, Aks SE, Hutson JR, Juurlink DN, Nguyen P, Dubnov-Raz G, et al. Colchicine poisoning: the dark side of an ancient drug. Clin Toxicol (Phila). 2010;48(5):407–14. https://doi.org/10.3109/15563650.2010.495348.CrossRefPubMed

37.

Crittenden DB, Lehmann RA, Schneck L, Keenan RT, Shah B, Greenberg JD, et al. Colchicine use is associated with decreased prevalence of myocardial infarction in patients with gout. J Rheumatol. 2012;39(7):1458–64. https://doi.org/10.3899/jrheum.111533.CrossRefPubMedPubMedCentral

38.

Shah B, Toprover M, Crittenden DB, Jeurling S, Pike VC, Krasnokutsky S, et al. Colchicine use and incident coronary artery disease in male patients with gout. Can J Cardiol. 2020;36(11):1722–8. https://doi.org/10.1016/j.cjca.2020.05.026.CrossRefPubMed

39.

Solomon DH, Liu CC, Kuo IH, Zak A, Kim SC. Effects of colchicine on risk of cardiovascular events and mortality among patients with gout: a cohort study using electronic medical records linked with Medicare claims. Ann Rheum Dis. 2016;75(9):1674–9. https://doi.org/10.1136/annrheumdis-2015-207984.CrossRefPubMed

40.

Langevitz P, Livneh A, Neumann L, Buskila D, Shemer J, Amolsky D, et al. Prevalence of ischemic heart disease in patients with familial Mediterranean fever. Isr Med Assoc J. 2001;3(1):9–12.PubMed

41.

Vaidya K, Arnott C, Martínez GJ, Ng B, McCormack S, Sullivan DR, et al. Colchicine therapy and plaque stabilization in patients with acute coronary syndrome: a CT coronary angiography study. JACC Cardiovasc Imaging. 2018;11(2 Pt 2):305–16. https://doi.org/10.1016/j.jcmg.2017.08.013.CrossRefPubMed

42.

Nidorf SM, Eikelboom JW, Budgeon CA, Thompson PL. Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol. 2013;61(4):404–10. https://doi.org/10.1016/j.jacc.2012.10.027.CrossRefPubMed

43.

Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies With the special contribution of the European Association of Preventive Cardiology (EAPC). Eur Heart J. 2021;42(34):3227–337. https://doi.org/10.1093/eurheartj/ehab484.CrossRefPubMed

44.

Ponte-Negretti CI, Wyss FS, Piskorz D, Santos RD, Villar R, Lorenzatti A, et al. Latin American Consensus on management of residual cardiometabolic risk. A consensus paper prepared by the Latin American Academy for the Study of Lipids and Cardiometabolic Risk (ALALIP) endorsed by the Inter-American Society of Cardiology (IASC), the International Atherosclerosis Society (IAS), and the Pan-American College of Endothelium (PACE). Arch Cardiol Mex. 2022;92(1):99–112. https://doi.org/10.24875/acm.21000005.CrossRefPubMed

45.

Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713–22. https://doi.org/10.1056/NEJMoa1615664.CrossRefPubMed

46.

Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379(22):2097–107. https://doi.org/10.1056/NEJMoa1801174.CrossRefPubMed

47.

Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):2387–97. https://doi.org/10.1056/NEJMoa1410489.CrossRefPubMed

48.

Nissen SE, Lincoff AM, Brennan D, Ray KK, Mason D, Kastelein JJP, et al. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. N Engl J Med. 2023;388(15):1353–64. https://doi.org/10.1056/NEJMoa2215024.CrossRefPubMed

49.

Marx N, Husain M, Lehrke M, Verma S, Sattar N. GLP-1 receptor agonists for the reduction of atherosclerotic cardiovascular risk in patients with type 2 diabetes. Circulation. 2022;146(24):1882–94. https://doi.org/10.1161/CIRCULATIONAHA.122.059595.CrossRefPubMed

50.

Cowie MR, Fisher M. SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control. Nat Rev Cardiol. 2020;17(12):761–72. https://doi.org/10.1038/s41569-020-0406-8.CrossRefPubMed

51.

Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O, et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med. 2017;377(14):1319–30. https://doi.org/10.1056/NEJMoa1709118.CrossRefPubMed

52.

Beezer J, Al Hatrushi M, Husband A, Kurdi A, Forsyth P. Polypharmacy definition and prevalence in heart failure: a systematic review. Heart Fail Rev. 2022;27(2):465–92. https://doi.org/10.1007/s10741-021-10135-4.CrossRefPubMed

53.

Ly DP, Giuriato MA, Song Z. Changes in prescription drug and health care use over 9 years after the large drug price increase for colchicine. JAMA Intern Med. 2023;183(7):670–6. https://doi.org/10.1001/jamainternmed.2023.0898.CrossRefPubMed

Titel: Colchicine for the Prevention of Cardiovascular Disease: Potential Global Implementation
verfasst von: Robert S. Zhang
Brittany N Weber
Diego Araiza-Garaygordobil
Michael S. Garshick
Publikationsdatum: 04.04.2024
Verlag: Springer US
Erschienen in: Current Cardiology Reports
Print ISSN: 1523-3782
Elektronische ISSN: 1534-3170
DOI: https://doi.org/10.1007/s11886-024-02049-y

Neu im Fachgebiet Kardiologie

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Colchicine for the Prevention of Cardiovascular Disease: Potential Global Implementation

Abstract

Purpose of Review

Recent Findings

Summary

Neu im Fachgebiet Kardiologie

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

Update Kardiologie

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Neu im Fachgebiet Kardiologie

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

Update Kardiologie